KPC(SH:600422)2020-04-10 16:00Financial Performance - Net profit attributable to shareholders decreased by 10.92% to CNY 91,828,663.92 year-on-year[11] - Operating income decreased by 11.83% to CNY 1,567,482,724.33 compared to the same period last year[11] - Basic earnings per share decreased by 11.25% to CNY 0.1207[11] - The company has seen an increase of 8.42% in net profit attributable to shareholders after deducting non-recurring gains and losses, reaching CNY 86,371,567.92[11] - Total operating revenue for Q1 2020 was ¥1,567,482,724.33, a decrease of 11.83% compared to ¥1,777,702,273.34 in Q1 2019[47] - Net profit for Q1 2020 was ¥93,930,350.84, a decrease of 10.27% from ¥104,661,285.51 in Q1 2019[47] - The company reported a total comprehensive income for the period of CNY 86,633,785.82, compared to CNY 61,518,982.30 in the previous year, marking a growth of about 40.7%[55] Assets and Liabilities - Total assets increased by 5.25% to CNY 7,825,547,589.64 compared to the end of the previous year[11] - Total liabilities increased to ¥3,387,206,446.86 from ¥3,100,785,610.80, reflecting a growth of approximately 9.23%[35] - Current liabilities rose to ¥3,053,603,689.51, up from ¥2,777,699,470.33, indicating an increase of about 9.91%[35] - Total current assets increased to ¥5,189,941,804.96, up from ¥4,801,861,045.63 at the beginning of the year[32] - Cash and cash equivalents reached ¥402,362,376.33, compared to ¥379,975,811.42, showing an increase of about 5.99%[37] - Total equity attributable to shareholders rose to ¥4,297,251,529.64 from ¥4,196,201,236.63, an increase of approximately 2.61%[37] Cash Flow - Net cash flow from operating activities improved significantly, increasing by 124.28% to CNY 26,203,489.86[11] - The net cash flow from operating activities improved significantly to ¥26,203,489.86, a 124.28% increase, attributed to better cash flow management and reduced expenses[22] - Cash flow from operating activities generated a net amount of CNY 26,203,489.86, a significant improvement from a net loss of CNY 107,926,400.96 in the previous year[55] - Net cash flow from operating activities reached CNY 608,435,301.04, up from CNY 317,941,911.51 in the same period last year, representing a 91.1% increase[60] Expenses - Research and development expenses decreased by 31.11% to ¥9,327,377.23, impacted by project delays due to the pandemic[20] - Sales expenses dropped by 35.17% to ¥422,900,222.52, mainly due to reduced marketing activities during the pandemic[20] - The company reported a significant decrease in other income by 84.60% to ¥4,293,389.51, primarily due to reduced tax refunds from subsidiaries[20] - The company’s financial expenses decreased by 48.47% to ¥4,950,054.77, mainly due to a reduction in loans compared to the previous year[20] Shareholder Information - The total number of shareholders reached 60,198 by the end of the reporting period[16] - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 30.87% of the shares and has pledged 106,428,266 shares[16] Investment Activities - The net cash flow from investing activities was negative at ¥-593,679,659.01, a 26.16% improvement compared to the previous period, mainly due to fluctuations in financial product purchases[22] - Investment activities resulted in a net cash outflow of CNY 593,679,659.01, compared to a net outflow of CNY 804,037,172.45 in the previous year[57] Future Plans - The company plans to repurchase shares using its own funds, with 50% of the repurchased shares to be canceled and the other 50% allocated for employee equity incentive plans[23] - The company intends to register and issue short-term financing bonds not exceeding ¥800 million to broaden its financing channels[24]